Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 22 2013
Print RSS Feed

Breaking News

Related Searches: Trials & Filings •
Sanofi, Regeneron Lung Cancer Trial Misses Endpoint

March 11, 2011
Sanofi-aventis and Regeneron Pharmaceuticals’ Phase III VITAL trial evaluating the investigational drug aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC) showed that adding aflibercept to the chemotherapy dr  Read More »
GNS, Biogen Idec Identify RA Drug Targets

March 11, 2011
GNS Healthcare and Biogen Idec published results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.   Read More »
Eli Lilly and Co.

March 10, 2011
Greg Plowman, M.D., Ph.D., has been appointed to lead Lilly’s oncology research efforts as the vice president of oncology research, and senior vice president of ImClone Systems research.  Read More »
Epizyme, Eisai Enter Epigenetic Enzyme Engagement

March 10, 2011
Epizyme, Inc. has entered a worldwide partnership with Eisai Co. to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers.  Read More »
Financial Report: Patheon 1Q11

March 10, 2011
Commercial manufacturing revenues were up 16% to $148.7 million  Read More »
Catalent’s Schorndorf Facility Marks 50 years

March 10, 2011
Catalent Pharma Solutions celebrates the 50th anniversary of its Schorndorf, Germany facility, which specializes in modified release technologies and clinical supply services.   Read More »
FDA Approves Benlysta for Lupus

March 10, 2011
Human Genome Sciences, Inc. and GlaxoSmithKline received approval from the FDA for Benlysta (belimumab) for the treatment of autoantibody-positive systemic lupus erythematosus (SLE) in patients receiving standard therapy.  Read More »
BMS, KineMed Extend Alzheimer’s Pact

March 9, 2011
Bristol-Myers Squibb and KineMed, Inc. have extended their research collaboration in the area of Alzheimer’s disease and other neurodegenerative conditions.   Read More »
Aeterna Zentaris, Yakult Honsha In Onco-Development Pact

March 9, 2011
Aeterna Zentaris, Inc. and Yakult Honsha Co. have signed an exclusive development, commercialization and licensing agreement for Aeterna Zentaris' lead anti-cancer compound perifosine, in Japan.  Read More »
Financial Report: WuXi PharmaTech

March 9, 2011
Growth in the quarter was driven by Lab Services revenue (+16%) and a 59% increase in Manufacturing Services revenues.  Read More »
Stemline AML Drug Gains Orphan Status

March 9, 2011
Stemline Therapeutics’ lead compound SL-401, has received Orphan Drug designation from FDA for the treatment of acute myeloid leukemia (AML).  Read More »
Hospira, Inc.

March 8, 2011
F. Michael (Mike) Ball has been appointed chief executive officer of Hospira, Inc. and a member of the board, effective March 28, 2011.  Read More »
RainDance Technologies, Ambry Genetics Enter ADME Pact

March 8, 2011
RainDance Technologies, Inc. and Ambry Genetics have entered a collaboration focused on the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion (ADME) genetic screening panel.  Read More »
Eisai Restructures U.S. Operations

March 8, 2011
Eisai, Inc., a U.S. subsidiary of Eisai Co., Ltd., plans to restructure its operations, cutting approximately 20% of its workforce across all U.S. functions, resulting in the loss of 600 positions by April 1, 2011.   Read More »
FDA Accepts Dapagliflozin NDA

March 8, 2011
Bristol-Myers Squibb and AstraZeneca’s NDA for dapagliflozin, an investigational drug for the treatment of type 2 diabetes, has been accepted by the FDA.   Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: